title: A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.
authors.affiliation: University of Rochester Medical Center, 601 Elmwood Avenue, Box 617, Rochester, NY, 14642, USA. Elizabeth_hansen@urmc.rochester.edu.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hansen
authors.affiliation: University of Rochester Medical Center, 601 Elmwood Avenue, Box 617, Rochester, NY, 14642, USA.
authors.forename: Deepak
authors.initials: D
authors.lastname: Sahasrabudhe
authors.affiliation: University of Rochester Medical Center, 601 Elmwood Avenue, Box 617, Rochester, NY, 14642, USA.
authors.forename: Lynn
authors.initials: L
authors.lastname: Sievert
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D019468:Disease Management; D006801:Humans; D061385:Insulins / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000009:adverse effects; D063868:Patient Outcome Assessment; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms; D016896:Treatment Outcome; D000096142:Cutaneous Malignant Melanoma
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D061385:Insulins; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab